{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06312176",
            "orgStudyIdInfo": {
                "id": "2870-010"
            },
            "secondaryIdInfos": [
                {
                    "id": "MK-2870-010",
                    "type": "OTHER",
                    "domain": "Merck"
                },
                {
                    "id": "2023-504918-29",
                    "type": "REGISTRY",
                    "domain": "EU CT"
                },
                {
                    "id": "U1111-1289-8119",
                    "type": "OTHER",
                    "domain": "UTN"
                }
            ],
            "organization": {
                "fullName": "Merck Sharp & Dohme LLC",
                "class": "INDUSTRY"
            },
            "briefTitle": "A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)",
            "officialTitle": "An Open-label, Randomized Phase 3 Study of MK-2870 as a Single Agent and in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "a-study-of-sacituzumab-tirumotecan-mk-as-a-single-agent-and-in-combination-with-pembrolizumab-mk-versus-treatment-of-physician-s-choice-in-participants-with-hr-unresectable-locally-advanced-or-metastatic-breast-cancer-mk"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-04-14",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2027-07-11",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2031-04-12",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-03-07",
            "studyFirstSubmitQcDate": "2024-03-07",
            "studyFirstPostDateStruct": {
                "date": "2024-03-15",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-26",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-29",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Merck Sharp & Dohme LLC",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The purpose of this study is to compare sacituzumab tirumotecan as a single agent, and in combination with pembrolizumab, versus Treatment of Physician's Choice (TPC) in participants with hormone receptor positive/human epidermal growth factor receptor-2 negative (HR+/HER2-) unresectable locally advanced, or metastatic, breast cancer.\n\nThe primary hypotheses are that sacituzumab tirumotecan as a single agent and sacituzumab tirumotecan plus pembrolizumab are superior to TPC with respect to progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) by blinded independent central review (BICR) in all participants."
        },
        "conditionsModule": {
            "conditions": [
                "Breast Neoplasms"
            ],
            "keywords": [
                "Programmed Cell Death-1 (PD1, PD-1)",
                "Programmed Cell Death 1 Ligand 1 (PDL1, PD-L1)",
                "Programmed Cell Death 1 Ligand 2 (PDL2, PD-L2)"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE3"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 1200,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Arm A: Sacituzumab tirumotecan",
                    "type": "EXPERIMENTAL",
                    "description": "Participants receive 4 mg/kg of sacituzumab tirumotecan once every 2 weeks (Q2W) via intravenous (IV) infusion until progressive disease or discontinuation.",
                    "interventionNames": [
                        "Drug: Sacituzumab tirumotecan"
                    ]
                },
                {
                    "label": "Arm B:Pembrolizumab + Sacituzumab tirumotecan",
                    "type": "EXPERIMENTAL",
                    "description": "Participants receive 4 mg/kg of sacituzumab tirumotecan Q2W via IV infusion until progressive disease or discontinuation PLUS 400 mg of pembrolizumab once every 6 weeks (Q6W) via IV infusion for up to 18 administrations (up to \\~2 years).",
                    "interventionNames": [
                        "Drug: Sacituzumab tirumotecan",
                        "Biological: Pembrolizumab"
                    ]
                },
                {
                    "label": "Arm C: Treatment of Physician's Choice (TPC)",
                    "type": "ACTIVE_COMPARATOR",
                    "description": "At the physician's discretion, participants receive chemotherapy of 80 mg/m\\^2 of paclitaxel once every week (Q1W) via IV infusion OR 90 mg/m\\^2 of paclitaxel once every 4 weeks (Q4W) via IV infusion OR 100 mg/m\\^2 of nab-paclitaxel Q4W via IV infusion OR 1000 mg/m\\^2 of capecitabine every 3 weeks (Q3W) orally OR 50 mg/m\\^2 of liposomal doxorubicin once every 4 weeks (Q4W) via IV infusion, until progressive disease or discontinuation.",
                    "interventionNames": [
                        "Drug: Paclitaxel",
                        "Drug: Nab-paclitaxel",
                        "Drug: Capecitabine",
                        "Drug: Liposomal doxorubicin"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Sacituzumab tirumotecan",
                    "description": "IV infusion",
                    "armGroupLabels": [
                        "Arm A: Sacituzumab tirumotecan",
                        "Arm B:Pembrolizumab + Sacituzumab tirumotecan"
                    ],
                    "otherNames": [
                        "MK-2870"
                    ]
                },
                {
                    "type": "BIOLOGICAL",
                    "name": "Pembrolizumab",
                    "description": "IV infusion",
                    "armGroupLabels": [
                        "Arm B:Pembrolizumab + Sacituzumab tirumotecan"
                    ],
                    "otherNames": [
                        "MK-3475",
                        "KEYTRUDA\u00ae"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Paclitaxel",
                    "description": "IV infusion",
                    "armGroupLabels": [
                        "Arm C: Treatment of Physician's Choice (TPC)"
                    ],
                    "otherNames": [
                        "TAXOL\u00ae"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Nab-paclitaxel",
                    "description": "IV infusion",
                    "armGroupLabels": [
                        "Arm C: Treatment of Physician's Choice (TPC)"
                    ],
                    "otherNames": [
                        "ABRAXANE\u00ae"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Capecitabine",
                    "description": "oral tablet",
                    "armGroupLabels": [
                        "Arm C: Treatment of Physician's Choice (TPC)"
                    ],
                    "otherNames": [
                        "XELODA\u00ae"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Liposomal doxorubicin",
                    "description": "IV infusion",
                    "armGroupLabels": [
                        "Arm C: Treatment of Physician's Choice (TPC)"
                    ],
                    "otherNames": [
                        "DOXIL\u00ae"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Progression-Free Survival (PFS) ( sacituzumab tirumotecan versus treatment of physician's choice [TPC]; pembrolizumab + sacituzumab tirumotecan versus TPC)",
                    "description": "PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first as assessed by Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1). PD is defined as \u226520% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of \u22655 mm. The appearance of one or more new lesions is also considered PD. PFS as assessed by blinded independent central review (BICR) will be presented.",
                    "timeFrame": "Up to ~38 months"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Overall Survival (OS)",
                    "description": "OS is defined as the time from randomization to death due to any cause.",
                    "timeFrame": "Up to ~77 months"
                },
                {
                    "measure": "Progression-Free Survival (PFS) (pembrolizumab + sacituzumab tirumotecan + versus sacituzumab tirumotecan)",
                    "description": "PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first as assessed by Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1). PD is defined as \u226520% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of \u22655 mm. The appearance of one or more new lesions is also considered PD. PFS as assessed by blinded independent central review (BICR) will be presented.",
                    "timeFrame": "Up to ~57 months"
                },
                {
                    "measure": "Objective Response Rate (ORR)",
                    "description": "ORR is defined as the percentage of participants with Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1). The percentage of participants who experience CR or PR as assessed by Blinded Independent Central Review (BICR) will be presented.",
                    "timeFrame": "Up to ~57 months"
                },
                {
                    "measure": "Duration of Response (DOR)",
                    "description": "For participants who demonstrate a confirmed Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1), DOR is defined as the time from first documented evidence of CR or PR until progressive disease (PD) or death. Per RECIST 1.1, PD is defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD. DOR as assessed by Blinded Independent Central Review (BICR) will be presented.",
                    "timeFrame": "Up to ~57 months"
                },
                {
                    "measure": "Change from baseline in global health status/quality of life scores, on the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30)",
                    "description": "The EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life of cancer patients. Participant responses to the questions \"How would you rate your overall health during the past week?\" and \"How would you rate your overall quality of life during the past week?\" are scored on a 7-point scale (1= Very poor to 7=Excellent). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A higher score indicates a better overall health status.",
                    "timeFrame": "Baseline and up to ~77 months"
                },
                {
                    "measure": "Change from baseline in physical functioning score, on the EORTC QLQ-C30",
                    "description": "The EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life of cancer patients. Participant responses to questions about their physical functioning are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A higher score indicates a better level of physical functioning.",
                    "timeFrame": "Baseline and up to ~77 months"
                },
                {
                    "measure": "Change from baseline in emotional functioning score, on the EORTC QLQ-C30",
                    "description": "The EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life of cancer patients. Participant responses to questions about their emotional functioning are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A higher score indicates a better level of emotional functioning.",
                    "timeFrame": "Baseline and up to ~77 months"
                },
                {
                    "measure": "Change from baseline in fatigue score, on the EORTC QLQ-C30",
                    "description": "The EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life of cancer patients. Participant responses to questions about their fatigue are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A lower score indicates a better level of function.",
                    "timeFrame": "Baseline and up to ~77 months"
                },
                {
                    "measure": "Change from baseline in diarrhea score, on the EORTC QLQ-C30",
                    "description": "The EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life of cancer patients. Participant responses to the question \"Have you had diarrhea?\" are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A lower score indicates a better level of function.",
                    "timeFrame": "Baseline and up to ~77 months"
                },
                {
                    "measure": "Time to first Deterioration (TTD) in global health status/quality of life scores, on the EORTC QLQ-C30",
                    "description": "The EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life of cancer patients. Participant responses to the questions \"How would you rate your overall health during the past week?\" and \"How would you rate your overall quality of life during the past week?\" are scored on a 7-point scale (1= Very poor to 7=Excellent). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A higher score indicates a better overall health status. TTD is defined as the time from baseline to the first onset of a 10-point deterioration from baseline in global health status/quality of life combined score.",
                    "timeFrame": "Up to ~77 months"
                },
                {
                    "measure": "TTD in physical functioning score, on the EORTC QLQ-C30",
                    "description": "The EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life of cancer patients. Participant responses to questions about their physical functioning are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A higher score indicates a better level of physical functioning. TTD is defined as the time from baseline to the first onset of a 10-point deterioration from baseline in the physical functioning score.",
                    "timeFrame": "Up to ~77 months"
                },
                {
                    "measure": "TTD in emotional functioning score, on the EORTC QLQ-C30",
                    "description": "The EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life of cancer patients. Participant responses to questions about their emotional functioning are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A higher score indicates a better level of emotional functioning. TD is defined as the time from baseline to the first onset of a 10-point deterioration from baseline in the emotional functioning score.",
                    "timeFrame": "Up to ~77 months"
                },
                {
                    "measure": "TTD in fatigue score, on the EORTC QLQ-C30",
                    "description": "The EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life of cancer patients. Participant responses to questions about their fatigue are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A lower score indicates a better level of function. TTD is defined as the time from baseline to the first onset of a 10-point deterioration from baseline in the fatigue score.",
                    "timeFrame": "Up to ~77 months"
                },
                {
                    "measure": "TTD in diarrhea score, on the EORTC QLQ-C30",
                    "description": "The EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life of cancer patients. Participant responses to the question about their diarrhea are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A lower score indicates a better level of function. TTD is defined as the time from baseline to the first onset of a 10-point deterioration from baseline in the diarrhea score.",
                    "timeFrame": "Up to ~77 months"
                },
                {
                    "measure": "Number of participants who experience one or more adverse events (AEs)",
                    "description": "An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.",
                    "timeFrame": "Up to ~77 months"
                },
                {
                    "measure": "Number of participants who discontinue study treatment due to an AE",
                    "description": "An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.",
                    "timeFrame": "Up to ~77 months"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Has unresectable locally advanced or metastatic centrally-confirmed hormone receptor positive (HR+)/human epidermal growth factor receptor 2 negative (HER2-) breast cancer\n* Has radiographic disease progression on one or more lines of endocrine therapy for unresectable locally advanced/metastatic HR+/HER2- breast cancer, with one in combination with a CDK4/6 inhibitor\n* Is a chemotherapy candidate\n* Has an eastern cooperative oncology group (ECOG) performance status of 0 to 1 assessed within 7 days before randomization\n* Has adequate organ function\n* Human immunodeficiency virus (HIV)-infected participants must have well controlled HIV on antiretroviral therapy\n* Participants who are Hepatitis B surface antigen (HBsAg) positive are eligible if they have received HBV antiviral therapy for at least 4 weeks, and have undetectable HBV viral load\n* Participants with a history of Hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable\n\nExclusion Criteria:\n\n* Has breast cancer amenable to treatment with curative intent\n* Has experienced an early recurrence (\\<6 months after completing adjuvant/neoadjuvant chemotherapy) and therefore is eligible to receive second-line (2L) treatment\n* Has symptomatic advanced/metastatic visceral spread at risk of rapidly evolving into life-threatening complications\n* Has received prior chemotherapy for unresectable locally advanced or metastatic breast cancer\n* Active autoimmune disease that has required systemic treatment in the past 2 years\n* History of (noninfectious) pneumonitis/interstitial lung disease that requires steroids, or has current pneumonitis/interstitial lung disease\n* Has an active infection requiring systemic therapy",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Toll Free Number",
                    "role": "CONTACT",
                    "phone": "1-888-577-8839",
                    "email": "Trialsites@merck.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Medical Director",
                    "affiliation": "Merck Sharp & Dohme LLC",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "Mercy Medical Center - Baltimore-Medical Oncology and Hematology ( Site 0028)",
                    "status": "RECRUITING",
                    "city": "Baltimore",
                    "state": "Maryland",
                    "zip": "21202",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Study Coordinator",
                            "role": "CONTACT",
                            "phone": "410-783-5858"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.29038,
                        "lon": -76.61219
                    }
                },
                {
                    "facility": "Hematology Oncology Associates of Rockland ( Site 0054)",
                    "status": "RECRUITING",
                    "city": "Nyack",
                    "state": "New York",
                    "zip": "10960",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Study Coordinator",
                            "role": "CONTACT",
                            "phone": "845-480-7440"
                        }
                    ],
                    "geoPoint": {
                        "lat": 41.09065,
                        "lon": -73.91791
                    }
                },
                {
                    "facility": "Stony Brook University-Cancer Center ( Site 0034)",
                    "status": "RECRUITING",
                    "city": "Stony Brook",
                    "state": "New York",
                    "zip": "11794",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Study Coordinator",
                            "role": "CONTACT",
                            "phone": "520-349-1302"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.92565,
                        "lon": -73.14094
                    }
                },
                {
                    "facility": "Fundacion Estudios Clinicos-Oncology ( Site 0384)",
                    "status": "RECRUITING",
                    "city": "Rosario",
                    "state": "Santa Fe",
                    "zip": "S2000DEJ",
                    "country": "Argentina",
                    "contacts": [
                        {
                            "name": "Study Coordinator",
                            "role": "CONTACT",
                            "phone": "+5493469699922"
                        }
                    ],
                    "geoPoint": {
                        "lat": -32.94682,
                        "lon": -60.63932
                    }
                },
                {
                    "facility": "Hospital Aleman-Oncology ( Site 0386)",
                    "status": "RECRUITING",
                    "city": "Buenos Aires",
                    "zip": "C1118AAT",
                    "country": "Argentina",
                    "contacts": [
                        {
                            "name": "Study Coordinator",
                            "role": "CONTACT",
                            "phone": "541148277000x2306"
                        }
                    ],
                    "geoPoint": {
                        "lat": -34.61315,
                        "lon": -58.37723
                    }
                },
                {
                    "facility": "Hospital Italiano de C\u00f3rdoba ( Site 0385)",
                    "status": "RECRUITING",
                    "city": "Cordoba",
                    "zip": "X5004BAL",
                    "country": "Argentina",
                    "contacts": [
                        {
                            "name": "Study Coordinator",
                            "role": "CONTACT",
                            "phone": "3515054293"
                        }
                    ],
                    "geoPoint": {
                        "lat": -31.4135,
                        "lon": -64.18105
                    }
                },
                {
                    "facility": "Frankston Hospital-Oncology and Haematology ( Site 2003)",
                    "status": "RECRUITING",
                    "city": "Frankston",
                    "state": "Victoria",
                    "zip": "3199",
                    "country": "Australia",
                    "contacts": [
                        {
                            "name": "Study Coordinator",
                            "role": "CONTACT",
                            "phone": "61397856344"
                        }
                    ],
                    "geoPoint": {
                        "lat": -38.14458,
                        "lon": 145.12291
                    }
                },
                {
                    "facility": "Oncovida ( Site 0453)",
                    "status": "RECRUITING",
                    "city": "Santiago",
                    "state": "Region M. De Santiago",
                    "zip": "7510032",
                    "country": "Chile",
                    "contacts": [
                        {
                            "name": "Study Coordinator",
                            "role": "CONTACT",
                            "phone": "5624205100"
                        }
                    ],
                    "geoPoint": {
                        "lat": -33.45694,
                        "lon": -70.64827
                    }
                },
                {
                    "facility": "Cl\u00ednica RedSalud Vitacura ( Site 0455)",
                    "status": "RECRUITING",
                    "city": "Santiago",
                    "state": "Region M. De Santiago",
                    "zip": "7650018",
                    "country": "Chile",
                    "contacts": [
                        {
                            "name": "Study Coordinator",
                            "role": "CONTACT",
                            "phone": "56982926243"
                        }
                    ],
                    "geoPoint": {
                        "lat": -33.45694,
                        "lon": -70.64827
                    }
                },
                {
                    "facility": "Pontificia Universidad Catolica de Chile-Centro del C\u00e1ncer ( Site 0454)",
                    "status": "RECRUITING",
                    "city": "Santiago",
                    "state": "Region M. De Santiago",
                    "zip": "8330032",
                    "country": "Chile",
                    "contacts": [
                        {
                            "name": "Study Coordinator",
                            "role": "CONTACT",
                            "phone": "56223546919"
                        }
                    ],
                    "geoPoint": {
                        "lat": -33.45694,
                        "lon": -70.64827
                    }
                },
                {
                    "facility": "CIMCA ( Site 0551)",
                    "status": "RECRUITING",
                    "city": "San Jos\u00e9",
                    "state": "San Jose",
                    "zip": "10103",
                    "country": "Costa Rica",
                    "contacts": [
                        {
                            "name": "Study Coordinator",
                            "role": "CONTACT",
                            "phone": "50683893636"
                        }
                    ],
                    "geoPoint": {
                        "lat": 9.93333,
                        "lon": -84.08333
                    }
                },
                {
                    "facility": "Hospital Metropolitano - Sede Lindora ( Site 0550)",
                    "status": "RECRUITING",
                    "city": "Santa Ana",
                    "state": "San Jose",
                    "zip": "10903",
                    "country": "Costa Rica",
                    "contacts": [
                        {
                            "name": "Study Coordinator",
                            "role": "CONTACT",
                            "phone": "50684978912"
                        }
                    ],
                    "geoPoint": {
                        "lat": 9.9326,
                        "lon": -84.18255
                    }
                },
                {
                    "facility": "ICIMED ( Site 0552)",
                    "status": "RECRUITING",
                    "city": "San Jose",
                    "zip": "10108",
                    "country": "Costa Rica",
                    "contacts": [
                        {
                            "name": "Study Coordinator",
                            "role": "CONTACT",
                            "phone": "506 88317449"
                        }
                    ],
                    "geoPoint": {
                        "lat": 9.93333,
                        "lon": -84.08333
                    }
                },
                {
                    "facility": "Queen Mary Hospital ( Site 2040)",
                    "status": "RECRUITING",
                    "city": "Hksar",
                    "country": "Hong Kong",
                    "contacts": [
                        {
                            "name": "Study Coordinator",
                            "role": "CONTACT",
                            "phone": "+852 39103299"
                        }
                    ]
                },
                {
                    "facility": "Prince of Wales Hospital ( Site 2041)",
                    "status": "RECRUITING",
                    "city": "Shatin",
                    "country": "Hong Kong",
                    "contacts": [
                        {
                            "name": "Study Coordinator",
                            "role": "CONTACT",
                            "phone": "85235051042"
                        }
                    ],
                    "geoPoint": {
                        "lat": 22.38333,
                        "lon": 114.18333
                    }
                },
                {
                    "facility": "Rambam Health Care Campus-Oncology Division ( Site 1452)",
                    "status": "RECRUITING",
                    "city": "Haifa",
                    "zip": "3109601",
                    "country": "Israel",
                    "contacts": [
                        {
                            "name": "Study Coordinator",
                            "role": "CONTACT",
                            "phone": "972-4-777-6700"
                        }
                    ],
                    "geoPoint": {
                        "lat": 32.81841,
                        "lon": 34.9885
                    }
                },
                {
                    "facility": "Hadassah Medical Center ( Site 1451)",
                    "status": "RECRUITING",
                    "city": "Jerusalem",
                    "zip": "9112001",
                    "country": "Israel",
                    "contacts": [
                        {
                            "name": "Study Coordinator",
                            "role": "CONTACT",
                            "phone": "972542626027"
                        }
                    ],
                    "geoPoint": {
                        "lat": 31.76904,
                        "lon": 35.21633
                    }
                },
                {
                    "facility": "Rabin Medical Center ( Site 1453)",
                    "status": "RECRUITING",
                    "city": "Petah Tikva",
                    "zip": "4941 492",
                    "country": "Israel",
                    "contacts": [
                        {
                            "name": "Study Coordinator",
                            "role": "CONTACT",
                            "phone": "972504065625"
                        }
                    ],
                    "geoPoint": {
                        "lat": 32.08707,
                        "lon": 34.88747
                    }
                },
                {
                    "facility": "Sheba Medical Center ( Site 1450)",
                    "status": "RECRUITING",
                    "city": "Ramat Gan",
                    "zip": "5265601",
                    "country": "Israel",
                    "contacts": [
                        {
                            "name": "Study Coordinator",
                            "role": "CONTACT",
                            "phone": "972543212828"
                        }
                    ],
                    "geoPoint": {
                        "lat": 32.08227,
                        "lon": 34.81065
                    }
                },
                {
                    "facility": "Seoul National University Hospital-Internal Medicine ( Site 2353)",
                    "status": "RECRUITING",
                    "city": "Seoul",
                    "zip": "03080",
                    "country": "Korea, Republic of",
                    "contacts": [
                        {
                            "name": "Study Coordinator",
                            "role": "CONTACT",
                            "phone": "02-2072-0850"
                        }
                    ],
                    "geoPoint": {
                        "lat": 37.566,
                        "lon": 126.9784
                    }
                },
                {
                    "facility": "Severance Hospital, Yonsei University Health System-Medical oncology ( Site 2350)",
                    "status": "RECRUITING",
                    "city": "Seoul",
                    "zip": "03722",
                    "country": "Korea, Republic of",
                    "contacts": [
                        {
                            "name": "Study Coordinator",
                            "role": "CONTACT",
                            "phone": "82222288135"
                        }
                    ],
                    "geoPoint": {
                        "lat": 37.566,
                        "lon": 126.9784
                    }
                },
                {
                    "facility": "Asan Medical Center-Department of Oncology ( Site 2352)",
                    "status": "RECRUITING",
                    "city": "Seoul",
                    "zip": "05505",
                    "country": "Korea, Republic of",
                    "contacts": [
                        {
                            "name": "Study Coordinator",
                            "role": "CONTACT",
                            "phone": "82230103216"
                        }
                    ],
                    "geoPoint": {
                        "lat": 37.566,
                        "lon": 126.9784
                    }
                },
                {
                    "facility": "Samsung Medical Center-Division of Hematology/Oncology ( Site 2351)",
                    "status": "RECRUITING",
                    "city": "Seoul",
                    "zip": "06351",
                    "country": "Korea, Republic of",
                    "contacts": [
                        {
                            "name": "Study Coordinator",
                            "role": "CONTACT",
                            "phone": "821099331780"
                        }
                    ],
                    "geoPoint": {
                        "lat": 37.566,
                        "lon": 126.9784
                    }
                },
                {
                    "facility": "Pantai Hospital Kuala Lumpur ( Site 2151)",
                    "status": "RECRUITING",
                    "city": "Kuala Lumpur",
                    "zip": "59100",
                    "country": "Malaysia",
                    "contacts": [
                        {
                            "name": "Study Coordinator",
                            "role": "CONTACT",
                            "phone": "60322960800"
                        }
                    ],
                    "geoPoint": {
                        "lat": 3.1412,
                        "lon": 101.68653
                    }
                },
                {
                    "facility": "Puerto Rico Medical Research Center LLC ( Site 0675)",
                    "status": "RECRUITING",
                    "city": "Hato Rey",
                    "zip": "00917",
                    "country": "Puerto Rico",
                    "contacts": [
                        {
                            "name": "Study Coordinator",
                            "role": "CONTACT",
                            "phone": "7872968394"
                        }
                    ]
                },
                {
                    "facility": "University Hospital Basel-Gynecology & Gynecologic Oncology ( Site 1844)",
                    "status": "RECRUITING",
                    "city": "Basel",
                    "state": "Basel-Stadt",
                    "zip": "4031",
                    "country": "Switzerland",
                    "contacts": [
                        {
                            "name": "Study Coordinator",
                            "role": "CONTACT",
                            "phone": "+41 61 328 73 31"
                        }
                    ],
                    "geoPoint": {
                        "lat": 47.55839,
                        "lon": 7.57327
                    }
                },
                {
                    "facility": "Spital Thun ( Site 1840)",
                    "status": "RECRUITING",
                    "city": "Thun",
                    "state": "Berne",
                    "zip": "3600",
                    "country": "Switzerland",
                    "contacts": [
                        {
                            "name": "Study Coordinator",
                            "role": "CONTACT",
                            "phone": "+41586362645"
                        }
                    ],
                    "geoPoint": {
                        "lat": 46.75118,
                        "lon": 7.62166
                    }
                },
                {
                    "facility": "Brust-Zentrum ( Site 1841)",
                    "status": "RECRUITING",
                    "city": "Z\u00fcrich",
                    "state": "Zurich",
                    "zip": "8008",
                    "country": "Switzerland",
                    "contacts": [
                        {
                            "name": "Study Coordinator",
                            "role": "CONTACT",
                            "phone": "+41794580632"
                        }
                    ],
                    "geoPoint": {
                        "lat": 47.36667,
                        "lon": 8.54999
                    }
                },
                {
                    "facility": "Changhua Christian Hospital ( Site 2410)",
                    "status": "RECRUITING",
                    "city": "Changhua County",
                    "state": "Changhua",
                    "zip": "50006",
                    "country": "Taiwan",
                    "contacts": [
                        {
                            "name": "Study Coordinator",
                            "role": "CONTACT"
                        }
                    ]
                },
                {
                    "facility": "National Cheng Kung University Hospital-Surgery ( Site 2411)",
                    "status": "RECRUITING",
                    "city": "Tainan",
                    "zip": "704",
                    "country": "Taiwan",
                    "contacts": [
                        {
                            "name": "Study Coordinator",
                            "role": "CONTACT",
                            "phone": "886623535354273"
                        }
                    ],
                    "geoPoint": {
                        "lat": 22.99083,
                        "lon": 120.21333
                    }
                },
                {
                    "facility": "Mackay Memorial Hospital ( Site 2412)",
                    "status": "RECRUITING",
                    "city": "Taipei",
                    "zip": "10449",
                    "country": "Taiwan",
                    "contacts": [
                        {
                            "name": "Study Coordinator",
                            "role": "CONTACT",
                            "phone": "+886225433535"
                        }
                    ],
                    "geoPoint": {
                        "lat": 25.04776,
                        "lon": 121.53185
                    }
                },
                {
                    "facility": "St Bartholomew's Hospital-Centre for Experimental Cancer Medicine ( Site 1940)",
                    "status": "RECRUITING",
                    "city": "London",
                    "state": "London, City Of",
                    "zip": "EC1A 7BE",
                    "country": "United Kingdom",
                    "contacts": [
                        {
                            "name": "Study Coordinator",
                            "role": "CONTACT",
                            "phone": "442078828498"
                        }
                    ],
                    "geoPoint": {
                        "lat": 51.50853,
                        "lon": -0.12574
                    }
                }
            ]
        },
        "referencesModule": {
            "seeAlsoLinks": [
                {
                    "label": "Merck Clinical Trials Information",
                    "url": "https://www.merckclinicaltrials.com/"
                },
                {
                    "label": "Plain Language Summary",
                    "url": "https://trialstransparency.merckclinicaltrials.com/Study.aspx?id=2870-010&kw=2870-010"
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "YES",
            "description": "http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf",
            "url": "http://engagezone.msd.com/ds_documentation.php"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000001943",
                    "term": "Breast Neoplasms"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000001941",
                    "term": "Breast Diseases"
                },
                {
                    "id": "D000012871",
                    "term": "Skin Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M5220",
                    "name": "Breast Neoplasms",
                    "asFound": "Breast Neoplasms",
                    "relevance": "HIGH"
                },
                {
                    "id": "M6845",
                    "name": "Death",
                    "relevance": "LOW"
                },
                {
                    "id": "M5218",
                    "name": "Breast Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M15674",
                    "name": "Skin Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC17",
                    "name": "Skin and Connective Tissue Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000017239",
                    "term": "Paclitaxel"
                },
                {
                    "id": "D000068196",
                    "term": "Albumin-Bound Paclitaxel"
                },
                {
                    "id": "C000582435",
                    "term": "Pembrolizumab"
                },
                {
                    "id": "D000004317",
                    "term": "Doxorubicin"
                },
                {
                    "id": "C000506643",
                    "term": "Liposomal doxorubicin"
                },
                {
                    "id": "D000069287",
                    "term": "Capecitabine"
                }
            ],
            "ancestors": [
                {
                    "id": "D000000972",
                    "term": "Antineoplastic Agents, Phytogenic"
                },
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                },
                {
                    "id": "D000050257",
                    "term": "Tubulin Modulators"
                },
                {
                    "id": "D000050256",
                    "term": "Antimitotic Agents"
                },
                {
                    "id": "D000050258",
                    "term": "Mitosis Modulators"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000074322",
                    "term": "Antineoplastic Agents, Immunological"
                },
                {
                    "id": "D000082082",
                    "term": "Immune Checkpoint Inhibitors"
                },
                {
                    "id": "D000000903",
                    "term": "Antibiotics, Antineoplastic"
                },
                {
                    "id": "D000059005",
                    "term": "Topoisomerase II Inhibitors"
                },
                {
                    "id": "D000059003",
                    "term": "Topoisomerase Inhibitors"
                },
                {
                    "id": "D000004791",
                    "term": "Enzyme Inhibitors"
                },
                {
                    "id": "D000000964",
                    "term": "Antimetabolites, Antineoplastic"
                },
                {
                    "id": "D000000963",
                    "term": "Antimetabolites"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M7492",
                    "name": "Doxorubicin",
                    "asFound": "Cognitive",
                    "relevance": "HIGH"
                },
                {
                    "id": "M349416",
                    "name": "Pembrolizumab",
                    "asFound": "Mg/m2",
                    "relevance": "HIGH"
                },
                {
                    "id": "M19537",
                    "name": "Paclitaxel",
                    "asFound": "Sessions",
                    "relevance": "HIGH"
                },
                {
                    "id": "M377",
                    "name": "Capecitabine",
                    "asFound": "200",
                    "relevance": "HIGH"
                },
                {
                    "id": "M231",
                    "name": "Albumin-Bound Paclitaxel",
                    "asFound": "Sessions",
                    "relevance": "HIGH"
                },
                {
                    "id": "M227339",
                    "name": "Liposomal doxorubicin",
                    "asFound": "Administered intravenously",
                    "relevance": "HIGH"
                },
                {
                    "id": "M26197",
                    "name": "Tubulin Modulators",
                    "relevance": "LOW"
                },
                {
                    "id": "M26196",
                    "name": "Antimitotic Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M1346",
                    "name": "Antineoplastic Agents, Immunological",
                    "relevance": "LOW"
                },
                {
                    "id": "M2342",
                    "name": "Immune Checkpoint Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M4222",
                    "name": "Anti-Bacterial Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M4224",
                    "name": "Antibiotics, Antitubercular",
                    "relevance": "LOW"
                },
                {
                    "id": "M29348",
                    "name": "Topoisomerase Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M7951",
                    "name": "Enzyme Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M4281",
                    "name": "Antimetabolites",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "Infe",
                    "name": "Anti-Infective Agents"
                }
            ]
        }
    },
    "hasResults": false
}